Freedom Study: Myfortic in Kidney Transplant Patients

Sponsor
Novartis Pharmaceuticals (Industry)
Overall Status
Completed
CT.gov ID
NCT00101738
Collaborator
(none)
342
44
26
7.8
0.3

Study Details

Study Description

Brief Summary

The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
342 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Study to Investigate the Clinical Outcomes of Different Regimens of Myfortic® in De Novo Kidney Tx Pts Using Simulect® and Neoral® With or Without Steroids
Study Start Date :
Mar 1, 2003
Actual Primary Completion Date :
May 1, 2005
Actual Study Completion Date :
May 1, 2005

Outcome Measures

Primary Outcome Measures

  1. Calculated glomerular filtration rate after 12 months treatment []

Secondary Outcome Measures

  1. Incidence of death, graft loss, biopsy-proven acute rejection after 3 and 12 months. []

  2. Patient and graft survival after 12 months. []

  3. Incidence of AEs and SAEs after 3 and 12 months. []

  4. Blood pressure, lipids and glucose profiles after 3 and 12 months. []

  5. Percentage of patients free of steroids at 12 months []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Males and females aged 18 to 75 years.

  • Recipients of first, heart-beating cadaveric, living unrelated or living related non-HLA identical donor kidney transplant, treated with Simulect® and Neoral® as primary immunosuppression.

Exclusion Criteria:
  • Second or subsequent kidney transplant or multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any other organ.

  • Kidneys from non-heart beating donors or HLA identical living related donors.

  • ABO incompatibility against the donor.

Contacts and Locations

Locations

Site City State Country Postal Code
1 UCSF Kidney Transplant Service San Francisco California United States 94143-0780
2 Livelink, Inc. Tampa Florida United States 33606
3 Loyola Medical Center Maywood Illinois United States 60153
4 Indiana U. Medical Center Indianapolis Indiana United States 46202
5 University of Michigan Health System Ann Arbor Michigan United States 48109
6 University Hospitals of Cleveland, Division of Nephrology Cleveland Ohio United States 44106
7 Ohio State University Medical Center Columbus Ohio United States 43210
8 Legacy Research & Technology Ctr. Portland Oregon United States 97232
9 U. of Wisconsin Hospital Clinics Madison Wisconsin United States 53792-7375
10 Crai Norte San Martin Buenos Aires Argentina 1650
11 Hospital Cordoba Cordoba Argentina 5000
12 Unidad de Transplante Velez Sarsfield Cordoba Argentina X5016JDA
13 Royal Prince Alfred Hospital Camperdown New South Wales Australia 2050
14 Princess Alexandra Hospital Woolloongabba Queensland Australia 4102
15 The Queen Elizabeth Hospital Woodville South Australia Australia 5011
16 Monash Medical Centre Clayton Victoria Australia 3168
17 Royal Melbourne Hospital Parkville Victoria Australia 3052
18 Hospital das Clinicas - UNICAMP Campinas SP Brazil 13083-970
19 Hipertensao Hospital do Rim e Hipertensao Sao Paulo SP Brazil 04023 900
20 Foothills Medical Center Calgary Alberta Canada T2N 2T9
21 University of Alberta Hospital Edmonton Alberta Canada T6G 2B7
22 Queen II Health and Science Center Halifax Nova Scotia Canada B3H 2Y6
23 St. Michael's Hospital Toronto Ontario Canada M5C 2T2
24 University Health Network, The Toronto Hospital Toronto Ontario Canada M5G 2C4
25 McGill University Health Centre Montreal Quebec Canada H3A 1A1
26 Royal University Hospital Saskatoon Saskatchewan Canada S7N 0W8
27 Klinikum der Johann Wolfgang Geothe-Universitaet Frankfurt am Main Germany 60596
28 Staedt. Krankenhaus Koeln-Merheim Koeln Germany 51109
29 Ospedale Consorziale e policlinico-Universita degli Studi Bari BA Italy 70124
30 Hospital Kuala Lumpur Kuala Lumpur Malaysia 50586
31 Auckland Hospital Auckland Grafton New Zealand
32 Singapore General Hospital Singapore Singapore 169608
33 Hospital de Bellvitge L'hospitalet de Llobregat Spain 08907
34 Hospital Clinico San Carlos Madrid Spain 28040
35 Hospital Central de Asturias Oviedo Spain 33006
36 Chang-Gung Memorial Hospital-Linko Tao-Yuan Lin-Ko Taiwan 333
37 Taipei Veterans General Hospital Taipei ROC Taiwan
38 National Taiwan University Hospital Taipei Taiwan 100
39 Queen Elizabeth Medical Centre Edgbaston Birmingham United Kingdom B15 2TH
40 University Hospital of Wales Heath Park Cardiff United Kingdom CF14 4XW
41 Walsgrave Hospital NHS Trust Walsgrave Coventry United Kingdom CV2 2DX
42 Freeman Hospital High Heaton Newcastle Upon Tyne United Kingdom NE7 7DN
43 Guy's Hospital London United Kingdom SE1 9RT
44 Nottingham City Hospital Nottingham United Kingdom NG5 1BP

Sponsors and Collaborators

  • Novartis Pharmaceuticals

Investigators

  • Study Director: Novartis, Novartis

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00101738
Other Study ID Numbers:
  • CERL080A2404
First Posted:
Jan 13, 2005
Last Update Posted:
Jan 31, 2011
Last Verified:
Jan 1, 2011
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 31, 2011